Hepatic drug metabolism and anesthesia

Area of Science:

• Anesthesiology
• Pharmacology
• Toxicology

Background:

• Anesthetic agents are primarily metabolized in the liver, influencing drug action duration and intensity.
• Hepatic metabolism converts compounds into excretable products, usually with lower pharmacologic activity.
• Exceptions exist where metabolites can exhibit higher activity or toxicity than the parent drug.

Purpose of the Study:

• To highlight the significance of hepatic drug metabolism in anesthesiology.
• To explain the role of cytochrome P-450 enzymes in intrahepatic metabolism.
• To discuss the implications of enzyme induction on anesthetic drug toxicity.

Main Methods:

• Review of anesthetic agent metabolism pathways.
• Analysis of cytochrome P-450 mediated oxidative reactions.
• Examination of enzyme induction effects on drug toxicity.

Main Results:

• Inorganic fluoride, a metabolite of methoxyflurane, causes high-output renal failure, exacerbated by induced enzyme activity.
• Patients with induced enzyme activity are at increased risk for methoxyflurane-related renal failure.
• Evidence suggests abnormal halothane metabolites, produced via alternate pathways with induced enzymes, may cause liver damage.

Conclusions:

• Hepatic metabolism and enzyme induction are critical factors in anesthetic drug safety.
• Understanding these processes is vital for predicting and preventing adverse drug reactions in anesthesiology.
• Methoxyflurane and halothane toxicity underscore the risks associated with altered drug metabolism during anesthesia.